Abstract 4136
Background
Breast cancer (BC) is the most common form of malignant tumor in women worldwide. 60-70% of BC are hormone receptor-positive (HR+), HER2-negative (HER2–). The purpose of this analysis was to enhance understanding on the epidemiology for women with PIK3CA-mutant HR+/HER2– metastatic breast cancer (mBC).
Methods
PIK3CA mutations were tested from tumor biopsy (N = 1617) and circulating tumor DNA (ctDNA) (N = 1466) from patients enrolled into BOLERO-2, BELLE-2 and BELLE-3, which are three randomized Phase III studies in HR+/HER2– mBC. Various PIK3CA mutation testing methods were applied, including Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) for tumor biopsies, as well as BEAMing and droplet digital PCR for ctDNA samples.
Results
Prevalence of the PIK3CA mutations among tissue biopsies ranged from 34.1% to 41.1% while prevalence of the PIK3CA mutations among liquid biopsies ranged from 27.5% to 43.3%. Besides gene-level analysis, the PIK3CA prevalence by hot spots and by exons was examined as well. Further, subgroup analysis of PIK3CA prevalence had been conducted based on patient cohort (2L vs 3L), mutation testing methods, ethnicity, biopsy source (primary tissue vs metastatic) and previous treatment.
Conclusions
PIK3CA mutations (specifically hotspots H1047R, E545K and E542K) frequently occur in HR+/HER2– mBC. The prevalence of PIK3CA mutations are in a relatively narrow range across the three randomized Phase III studies in HR+/HER2– mBC regardless of tissue types and testing methods.
Clinical trial identification
Legal entity responsible for the study
Novartis Pharma.
Funding
Novartis Pharma.
Editorial Acknowledgement
Disclosure
K. Wan: Employment: Novartis Pharma AG; Stock options: Novartis. Y.A. Wang, N. Babbar, M. Kaper, M. Fritzemeier: Employment: Novartis Pharmaceutical Corporation; Stock options: Novartis.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract